- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Pfizer Steps into the CAR-T Immunotherapy Field With Cellectis Deal
Pfizer's deal with the French company will ensure a market share in the promising immunooncology field.
U.S. drugmaker Pfizer, which failed last month in a $118 billion bid to buy AstraZeneca , said on Wednesday it had signed a deal with French biotech Cellectis to develop immunotherapy drugs in cancer.
Boosting the body's immune system to fight tumours is a hot area for drug research and was one of the factors that attracted Pfizer to Britain's AstraZeneca - along with the potential to cut costs and taxes. The technology used by Cellectis involves reprogramming immune system cells to hunt out cancer and represents a different approach to that used by drugs under development at AstraZeneca.
The French company's research is still at an early stage but it hopes to start clinical trials in 2015, initially with a drug for leukaemia that it has already partnered with unlisted pharmaceuticals group Servier.
Press release: http://reut.rs/1l2FNFt
Source: Reuters
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
